Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Total Current Liabilities (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Total Current Liabilities for 3 consecutive years, with $82.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 41.18% to $82.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $82.2 million, a 41.18% increase, with the full-year FY2025 number at $82.2 million, up 41.18% from a year prior.
  • Total Current Liabilities was $82.2 million for Q4 2025 at Nuvation Bio, up from $68.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $82.2 million in Q4 2025 to a low of $12.6 million in Q1 2023.
  • A 3-year average of $42.5 million and a median of $51.9 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 316.8% in 2024, then rose 15.41% in 2025.
  • Nuvation Bio's Total Current Liabilities stood at $14.0 million in 2023, then skyrocketed by 316.8% to $58.2 million in 2024, then surged by 41.18% to $82.2 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Total Current Liabilities are $82.2 million (Q4 2025), $68.1 million (Q3 2025), and $66.4 million (Q2 2025).